$STAR

STRIDES PHARMA SCIENCE LTD STRATEGIC STAKE SALE IN PIVOT PATH • Company to sell majority stake in subsidiary Pivot Path for ₹1,000 million • Ascent Capital to infuse ₹500 million primary capital into Pivot Path for growth • Post deal, Strides stake to reduce to 19.95%, reclassifying Pivot Path as Associate • Transaction expected to be completed by June 30, 2026 Impact: Positive – Unlocks value & brings strategic capital for subsidiary expansion